Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25815032 | 0.97 | KMT2A (0.45) | KMT2ANPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL25811806 | 0.90 | KMT2A (0.43) | KMT2ANPC1RAB9ACYP19A1TLR9 | |
| SCHEMBL25811960 | 0.88 | KMT2A (0.47) | KMT2ANPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL25811801 | 0.87 | KMT2A (0.61) | KMT2ANPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL25811995 | 0.85 | KMT2A (0.49) | KMT2ANPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL25811987 | 0.85 | KMT2A (0.58) | KMT2ANPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL25814053 | 0.82 | TLR9 (0.46) | KMT2ANPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL25811253 | 0.80 | KMT2A (0.69) | KMT2ACYP19A1TLR9TLR7TLR8 | |
| SCHEMBL25811982 | 0.79 | MAPT (0.53) | KMT2ANPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL25811234 | 0.79 | KMT2A (0.67) | KMT2ACYP19A1TLR9TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | KMT2A 981/4885NPC1 1099/4885RAB9A 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.